Seaport rounds out C-suite with new hires
Plus: Germany-based Topas taps new CEO, and updates from Quest, Nimbus and more
Weeks after its $100 million launch, neuropsychiatric therapies company Seaport Therapeutics Inc. named co-founder Michael Chen as CSO and hired Eric Green as COO. Chen was head of innovation at PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), the entity that founded Seaport, and Green was SVP, head of development programs at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Seaport also appointed Johnson & Johnson (NYSE:JNJ) veteran Denice Torres to its board.
Hamburg-based private company Topas Therapeutics GmbH named Hugo Fry CEO. The biotech is developing antigen-specific immune tolerance therapies for autoimmune disorders; its lead program is in Phase II testing to treat celiac disease. Fry was chief commercial officer of Imbria Pharmaceuticals Inc. and CBO at 20Med Therapeutics B.V...